Rui Yi

Shanghai, China Founded: 2018 • Age: 8 yrs
Genomics solutions are offered for healthcare and diagnostics.
Annual revenue $96,779 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Rui Yi

Rui Yi is a company based in Shanghai (China) founded in 2018. Rui Yi operates in a competitive market with competitors including Omniome, HitGen, Rejuvenate Bio, Novogene Corporation and NovellusDx, among others.

  • Headquarter Shanghai, China
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Realbio Advanced Systems Private Limited
  • Date of Incorporation 17 Aug, 2018
  • Jurisdiction Bangalore, Karnataka, India
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $96.78 K (USD)
    15.36
    as on Mar 31, 2022
  • Net Profit
    $693.06 (USD)
    708.81
    as on Mar 31, 2022
  • EBITDA
    $1.58 K (USD)
    116.54
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Rui Yi

Premium access

Detailed funding history for Rui Yi

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Rui Yi

Investments
Premium access

Investment portfolio details for Rui Yi

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Rui Yi

Premium access

Detailed financials for Rui Yi

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Rui Yi Comparisons

Rui Yi Primary company
Description
Genomics solutions are offered for healthcare and diagnostic...
Location
Shanghai, China
Founded Year
2018
Annual Revenue
$96.78 K (USD)
Net Profit
$693.06 (USD)
EBITDA
$1.58 K (USD)
Employees
Not available
Premium access

Peer comparison for Rui Yi

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Rui Yi

Rui Yi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, HitGen, Rejuvenate Bio, Novogene Corporation and NovellusDx, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Genome sequencing platform is provided for clinical diagnostics.
Locked Locked Locked
DNA-encoded libraries are developed for drug discovery applications.
Locked Locked Locked
Gene-editing platform and anti-aging therapy for dogs are developed.
Locked Locked Locked
Genomic services and solutions with NGS expertise are provided.
Locked Locked Locked
Developer of technology for precision cancer diagnosis and therapies
Locked Locked Locked
Meta-genomics platforms and services for microbiome studies are provided.
Premium access

Detailed competitors of Rui Yi

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Rui Yi

Premium access

Complete news archive for Rui Yi

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rui Yi

Rui Yi was founded in 2018.

Rui Yi is headquartered in Shanghai, China.

Annual revenue of Rui Yi is $96.78K as on Mar 31, 2022.

Rui Yi was founded in 2018 in Shanghai, China, within the biological gene technology and health services sector. High-throughput sequencing and personalized big data analysis solutions are provided to major hospitals and medical centers. Medical services are extended to end customers, while diagnostic techniques for bacteria incubation, livestock management, nutrition, and disease control are developed. Operations focus on genomics applications across healthcare and agricultural domains.

Rui Yi's top competitors include Novogene Corporation, BGI and Omniome.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available